MiNK Therapeutics announced the appointment of Dr. Robert Kadlec to its Board of Directors on October 31, 2024. Dr. Kadlec brings extensive expertise in biodefense, pandemic preparedness, and public health strategy to the company.
Dr. Kadlec previously served as the U.S. Senate-confirmed Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). In this role, he led interagency responses to public health emergencies and co-conceived Operation Warp Speed during the COVID-19 pandemic.
His appointment is expected to accelerate MiNK's iNKT cell platform for addressing critical infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ARDS), and other immune-related conditions. CEO Dr. Jennifer Buell stated that Dr. Kadlec's understanding of public health systems will be instrumental in advancing MiNK's strategic vision.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.